Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to expand access to weight loss medications through the NHS.

Until recently, the newest obesity medicines liraglutide, under various brand names, semaglutide, under the brand name Wegovy, and tirzepatide, under the brand name Mounjaro, have only been available via the National Health Service through specialist weight management services which are mainly hospital-based.

From 23 June, tirzepatide has started to become available in primary care, meaning it can be prescribed by general practitioners, or other competent prescribers. NHS England’s phased rollout within primary care will prioritise those with the greatest clinical need. Approximately 220,000 people are expected to benefit in the first three years of implementation. As part of the rollout plans, the NHS will look at different service models, including digital and community options. New approaches might enable access to be expanded more quickly. Progress will be reviewed in three years, and the roll out will be sped up if possible.

In addition, the 10-Year Health Plan sets out our ambition to build on these plans by testing innovative models of delivering weight loss services and treatments to patients.

On 12 August we announced an £85 million competition to fund the design and delivery of new community and primary care weight management pathways to support access to interventions such as weight loss medications. We expect tens of thousands of patients to directly benefit from increased access to interventions, such as GLP-1s. This will generate new evidence to inform the future commissioning and rollout of tirzepatide.